Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
about
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitusEfficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled TrialInsulin Degludec Aspart: The First Co-formulation of Insulin AnaloguesThe Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 DiabetesInsulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trialInsulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST® : SIMPLE USE).Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Clinical use of the co-formulation of insulin degludec and insulin aspart.A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analy
P2860
Q26777076-263507D0-2C28-41C6-B398-D02013A936F1Q28597145-A92A6EE6-FDC9-4336-BC51-CECA56FF9E7CQ33785168-6240DA5D-0C99-42D7-9BAF-55253D7437F8Q35894512-A56CDFCF-D8C7-43B6-8F72-886F04834B00Q37060869-BEE3DD14-0BA7-4084-B710-DFCBABAA4B8BQ37320243-CE3F2A7B-7942-4EC6-B434-E224ACD6B3ABQ37337300-86AEE015-7CE4-4B45-95F6-EABAAEC45309Q37344032-1E438570-1195-4FB7-9E9B-BE27DC948631Q37595962-8F69374B-171F-4272-9F58-E7BE617C5943Q37596013-8896212C-717A-460E-BBDC-82D19342A971Q37677863-D4869A1A-539A-49D4-875F-75D82114FE5AQ38692387-C5208F46-20EC-4AEA-A197-A4C05C850D7EQ38887939-C169A7D5-606E-4F1D-81B9-3DC7DF58FA80Q38970550-0BCDA751-54DF-45DD-81F2-3043DFC7E414Q40269490-059ED576-D594-46DF-B301-01F8498A0F1DQ40810515-78D4DCB1-DF37-4A7F-8A42-EC691E2DA9C0Q41259339-C01C5728-CABD-4D2D-8654-D6C5E0AB6D28Q41558812-BFC0C476-50D9-489C-A8D9-35BBF71EC9A3Q42329441-EA918959-A0E9-49B3-8953-B95E853CA5B1Q48576692-A412F3D7-6A2C-4C47-8D7B-E56AC912FFCCQ49928678-FEB63D64-126F-4598-9B92-2CFC072CD8FA
P2860
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Distinct Prandial and Basal Gl ...... with Type 1 Diabetes Mellitus
@ast
Distinct Prandial and Basal Gl ...... with Type 1 Diabetes Mellitus
@en
type
label
Distinct Prandial and Basal Gl ...... with Type 1 Diabetes Mellitus
@ast
Distinct Prandial and Basal Gl ...... with Type 1 Diabetes Mellitus
@en
prefLabel
Distinct Prandial and Basal Gl ...... with Type 1 Diabetes Mellitus
@ast
Distinct Prandial and Basal Gl ...... with Type 1 Diabetes Mellitus
@en
P2093
P2860
P1433
P1476
Distinct Prandial and Basal Gl ...... with Type 1 Diabetes Mellitus
@en
P2093
Carsten Roepstorff
Hanne Haahr
Leszek Nosek
Oliver Klein
Suresh Chenji
P2860
P2888
P304
P356
10.1007/S13300-014-0070-2
P577
2014-06-03T00:00:00Z
P5875
P6179
1007300078